Topic
Rheumatology research, explained
3 open-access rheumatology studies, each with a flashcard deck and a quiz.
- RIPK1 inhibitor GSK2982772 did not beat placebo on RA activity here
In 52 patients with moderate–severe RA on stable csDMARDs, oral GSK2982772 60 mg for 84 days was mainly assessed for safety; DAS28-CRP and ACR responses looked similar to placebo, without meaningful clinical improvement at tested exposures.
- Early RA synovium splits into two expression/histology groups
Targeted knee synovial biopsies from early RA patients clustered into two major gene-expression groups with different histological scores, showing molecular heterogeneity even early in disease.
- Seliciclib MTD is 400 mg in TNF-refractory RA (TRAFIC phase 1b)
In an open-label UK dose-finding trial of 15 TNF-refractory RA patients, the CDK inhibitor seliciclib’s maximum tolerated dose was 400 mg, aiming at synovial fibroblast proliferation rather than classic immune-cytokine targets alone.